Regulatory uniQure sets course to US filing for Huntington gene therapy PharmaphorumShares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.NeuroscienceRead full story pharminent June 17, 2026 (Last updated: June 18, 2026) Pharmaphorum Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington’s gene therapy AMT-130. Neuroscience Read full story Post navigation Previous: Jazz orchestrates a $4bn cancer alliance with AbCelleraNext: UniQure to file gene therapy for approval, reflecting major shifts at FDA Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026